-
May 21, 2024 | 
ophthalmologytimes.com | Hattie Hayes |Emily Kaiser Maharjan
May 21, 2024The agency approved Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis, Biogen) as biosimilars to Eylea (Regeneron Pharmaceuticals). On Monday, the United States Food and Drug Administration (FDA) announced its approval of two biosimilars as interchangeable with aflibercept 2 mg (Eylea).1 The agency approved aflibercept-jbvf (Yesafili, Biocon Biologics) and aflibercept-yszy (Opuviz, Samsung Bioepis, Biogen).
-
Jan 6, 2024 | 
optometrytimes.com | Emily Kaiser Maharjan
Catch up with what Optometry Times shared this week:By Carrie Roitstein, ODCarrie Roitstein, OD, explores the intricate connection between chronic stress and eye health, shedding light on the physiological changes triggered by stress hormones that impact the eyes. Clinical signs of stress-related eye issues include eyelid twitching, retinopathy, ocular surface disease, vision loss, pupil dilation, and more.
-
Dec 29, 2023 | 
ophthalmologytimes.com | Emily Kaiser Maharjan
Happy New Year! As is tradition in popular culture, it's time to wrap up the year with a list of what happened at Optometry Times. We traversed many topics together, from a large number of eye drop recalls due to contamination to the burgeoning pipeline of new eye care products, and the editors and staff appreciate your readership this year and look forward to forging ahead in 2024.
-
Dec 29, 2023 | 
optometrytimes.com | Emily Kaiser Maharjan
Catch up with what Optometry Times shared this week:By Marlisa Miller, Editorial Intern; Emily Kaiser Maharjan, Assistant Managing EditorAccording to a report by Technavio, the eyewear market is expected to experience booming growth between 2023 and 2027.
-
Dec 27, 2023 | 
optometrytimes.com | Marlisa Miller |Emily Kaiser Maharjan
December 27, 2023A report by Technavio indicates that lifestyle changes will increase eyewear sales across the globe. According to a report by Technavio, the eyewear market is expected to experience booming growth between 2023 and 2027.
-
Dec 26, 2023 | 
optometrytimes.com | Emily Kaiser Maharjan
Happy New Year! As is tradition in popular culture, it's time to wrap up the year with a list of what happened here at Optometry Times. We traversed many topics together, from a large number of eye drop recalls due to contamination to the burgeoning pipeline of new eye care products, and the editors and staff appreciate your readership this year and look forward to forging ahead in 2024.
-
Dec 23, 2023 | 
optometrytimes.com | Emily Kaiser Maharjan
Catch up with what Optometry Times shared this week:New protocols and technological processes may offer advanced characterization for choroidal nevusBy Leo P. Semes, OD, FAAOThis article presents a case study of a White patient who sought a second opinion after being diagnosed with a freckle in one eye. The patient, in good health, had a pigmented lesion in her left eye diagnosed as a choroidal nevus.
-
Dec 16, 2023 | 
optometrytimes.com | Emily Kaiser Maharjan
Catch up with what Optometry Times® shared this week:David Hutton, Managing Editor, Ophthalmology TimesiDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has received FDA approval following a new drug application (NDA) submission. Read more...
-
Dec 12, 2023 | 
optometrytimes.com | Emily Kaiser Maharjan
The Vision Council published a new report highlighting their research on parents’ awareness and experiences with myopia in children. The research report, which is titled “Focused inSights 2023: Parental Perspectives on Myopia,” reveals that many parents misunderstand or underestimate the threat of myopia.
-
Dec 11, 2023 | 
optometrytimes.com | Emily Kaiser Maharjan
December 11, 2023The multidisciplinary program aims to bring myopia management tools to under-resourced children across the US. There is a significant discrepancy in access to myopia management tools across the US, and CooperVision is teaming up with 3 US optometry schools to lessen it.
